By: Alex Zhavoronkov
Bryan Johnson, founder and chief executive officer of Kernel Holding SA, during the Milken Institute ... [+] Global Conference in Beverly Hills, California, U.S., on Wednesday, Oct. 20, 2021.
Alex Zhavoronkov is the Founder and CEO of Insilico Medicine, a company specializing in artificial intelligence for drug discovery and longevity research. He writes for Forbes, covering topics such as longevity biotechnology, AI in drug discovery, and the future of healthcare. His articles provide insights into the latest scientific advancements and their potential impact on the pharmaceutical industry.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Alex Zhavoronkov's coverage primarily focuses on the intersection of technology, healthcare, and pharmaceuticals. His interest in longevity biotechnology, AI in healthcare, drug discovery, and medical breakthroughs suggests a strong emphasis on innovative developments within these fields.
Given the specific nature of his article titles and topics covered, Alex would likely be interested in pitches that offer expert insights into cutting-edge technological advancements or scientific breakthroughs related to longevity biotechnology and artificial intelligence within the healthcare and pharmaceutical sectors.
As he often cites data and covers industry-specific events, potential sources should possess deep knowledge or involvement within these specialized areas to provide credible commentary. Furthermore, given his broad geographic focus (as no specific region is mentioned), globally relevant perspectives are likely to capture his attention.
This information evolves through artificial intelligence and human feedback. Improve this profile .